Are Compounded Semaglutides Safe?

Here's the honest answer: compounded semaglutide is not FDA-approved, and that is the single most important thing to understand before comparing compounded semaglutide to Wegovy® or Ozempic®. Compounded semaglutide is prepared by state-licensed compounding pharmacies rather than manufactured under an FDA approval, which places compounded semaglutide in a separate regulatory category with different oversight. That does not automatically make compounded semaglutide unsafe: pharmacy compounding is a lawful, long-standing part of American medicine, governed federally by sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act and by 21 CFR Part 216. But it does mean the trial evidence, the manufacturing controls, and the documented risk profile of compounded semaglutide are not identical to those of the FDA-approved branded products — and the FDA has published specific, documented concerns about compounded semaglutide that are worth reading before you decide.

One distinction runs through everything below, so we'll state it plainly once. The clinical trial results you have read about semaglutide were generated with the FDA-approved branded products. Those results describe Wegovy® and Ozempic®. Those results do not certify any compounded semaglutide preparation, and nothing on this page should be read as if they did.

What compounded semaglutide actually is

Compounding pharmacies prepare medications for individual patients rather than mass-manufacture them. Compounded semaglutide rose to prominence while the branded semaglutide products were in extended shortage, because a drug on the FDA's shortage list opens a compounding pathway that is otherwise closed.

The word “same molecule” deserves a closer look, because it is where most marketing quietly overreaches. The FDA-approved branded products contain the base form of semaglutide. The FDA has reported that some semaglutide products sold by compounders are instead salt forms — semaglutide sodium and semaglutide acetate — and the agency states that these salt forms “are different active ingredients than are used in the approved drugs.” The FDA adds that it does “not have information on whether these salts have the same chemical and pharmacologic properties as the active ingredient in the approved drug” and is “not aware of any lawful basis for their use in compounding” (FDA, updated June 15, 2026). So “it's the same molecule” is a claim to verify about a specific pharmacy's specific preparation, not a fact you can assume.

The key differences from the branded products:

• Regulatory status. Wegovy® and Ozempic® are FDA-approved products whose approved indications are set out in their FDA labeling. Compounded semaglutide preparations are not FDA-approved; oversight of compounded semaglutide comes primarily from state pharmacy boards and applicable USP standards (USP <795>/<797>). The FDA puts it directly: “compounded drugs are not FDA approved,” which means “the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed” (FDA).
• Evidence base. The published semaglutide trial program was conducted with the FDA-approved branded products. Compounded semaglutide preparations were not the products studied in those trials.
• Production model. Compounded semaglutide is prepared by a pharmacy rather than produced on an FDA-inspected commercial manufacturing line, which allows flexibility but also more batch-to-batch variability.

What the FDA has actually reported about compounded semaglutide

These are not hypotheticals. Each item below is something the FDA has published about compounded semaglutide specifically.

• Dosing errors, some serious. The FDA has received reports of adverse events, some requiring hospitalization, that may relate to overdoses from dosing errors with compounded semaglutide injectable products. In the majority of those reports, patients drew up more than the prescribed dose from a multiple-dose vial and “administered five to 20 times more than the intended dose of semaglutide.” Reported effects included nausea, vomiting, abdominal pain, fainting, headache, migraine, dehydration, acute pancreatitis and gallstones (FDA alert, July 26, 2024).
• Concentrations are not standardized. The FDA-approved injectable semaglutide products are dosed in milligrams and supplied in pre-filled pens. By contrast, the FDA reports that compounded semaglutide “concentrations also may vary depending on the compounder, and a single compounder may offer multiple concentrations” — which is precisely how milligram-to-unit conversion errors happen (FDA).
• Adverse-event reports, and likely undercounting. As of May 31, 2026, the FDA had received 990 reports of adverse events associated with compounded semaglutide. The FDA also notes that federal law does not require state-licensed pharmacies that are not outsourcing facilities to report adverse events to the agency, “so it is likely that adverse events from compounded versions of these drugs are underreported” (FDA).
• Strength that missed its label — documented, not alleged. Potency variability in compounded semaglutide is real and the FDA has caught it in writing. In a January 16, 2026 warning letter, the FDA found that a compounding pharmacy “released and distributed drug products with strengths that differed from their labeled amounts,” including a “Semaglutide 2.5mg/mL Injection [that] was subpotent… potency of 79.876%.” The FDA deemed that semaglutide injection adulterated under section 501(c) of the FD&C Act and its labeling false or misleading under section 502(a) (FDA warning letter, Boothwyn Pharmacy).
• Shipping and storage. Injectable GLP-1 drugs require refrigeration per their package inserts, and the FDA has received complaints that certain compounded GLP-1 drugs “arrived warm or with inadequate ice packs.” The FDA recommends not using any injectable GLP-1 drug that arrives warm (FDA).
• Outright fraud exists. The FDA reports awareness of fraudulent compounded semaglutide carrying false label information, including labels naming compounding pharmacies that do not exist (FDA).

Where compounded semaglutide stands with the FDA right now

This is the part that has changed most, and any page that still describes an open shortage pathway for semaglutide is out of date.

The FDA states that “tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's drug shortage list.” For state-licensed pharmacies and licensed prescribers compounding semaglutide injection products under section 503A, the FDA states that “the period of enforcement discretion… has ended” (FDA, updated April 2026). On April 30, 2026, the FDA went further and proposed to exclude semaglutide from the 503B bulks list entirely, “finding no clinical need for outsourcing facilities to compound” it, and opened public comment through June 29, 2026 (FDA press announcement).

What that means in plain terms: the broad, shortage-driven era of compounded semaglutide is over, and compounded semaglutide now has to qualify under the ordinary conditions of 503A — which turn on an individual prescription and a documented clinical determination for a specific patient. Whether compounded semaglutide is permissible and appropriate for you is a determination for your prescriber and a licensed pharmacy under those conditions. It is not something an article, or a checkout page, can decide for you. Anyone still selling compounded semaglutide on the strength of “there's a shortage” is working from a 2024 script.

What responsible sourcing looks like

The risks above are largely about how and where compounded semaglutide is prepared and prescribed. Risk is meaningfully reduced when:

• The preparation comes from a state-licensed compounding pharmacy operating under USP standards, and you can find out which pharmacy it is
• A medical provider licensed to practice in your state reviews your full health history before prescribing, sets your dose, and adjusts it over time
• Dosing instructions are explicit in the units on your syringe, and support is available when questions come up between visits — the FDA's dosing-error reports are overwhelmingly a units-and-vials problem
• You know exactly what you are getting — no one blurs the line between compounded semaglutide and the branded products

That last point is a value we hold firmly: compounded semaglutide is not the same product as Wegovy® or Ozempic®, and we will never describe it as if it were. The FDA lists “claims such as the compounded drug is the same as an FDA-approved drug” as a warning sign of a company you should not buy from (FDA). We agree with them.

Compounded vs. brand-name: how to think about the choice

• Brand-name (Wegovy®, Ozempic®) — FDA-approved, produced under FDA-regulated manufacturing, and directly supported by the published semaglutide trials. Typically the most expensive path on a self-pay basis.
• Compounded semaglutide — not FDA-approved, prepared by state-licensed pharmacies, and subject to the FDA concerns documented above. Through Ladies First, plans that include compounded semaglutide start at $219 per 28 days of medication on a 12-week plan ($249 per 28 days on a flexible plan) — with provider visits, coaching, and shipping included.

Neither option is a shopping decision. Which medication fits your health history — branded or compounded, semaglutide or something else entirely — is a determination your medical provider makes during intake.

Red flags, whatever you choose

Contact your medical provider promptly if your medication looks different than usual (color, clarity, particles), if your side effects suddenly change in character or severity on the same dose, if you notice no effect at all where there was one, or if injection-site reactions worsen. Do not use any injectable semaglutide that arrives warm or without adequate refrigeration.

Severe abdominal pain deserves its own line. Semaglutide labeling for chronic weight management warns that acute pancreatitis has been observed in patients treated with GLP-1 receptor agonists, describes the symptom as severe abdominal pain that sometimes radiates to the back, and instructs patients to discontinue semaglutide promptly and contact their provider if pancreatitis is suspected (Wegovy® FDA labeling, DailyMed). That labeling describes the FDA-approved branded product. It is cited here because it is the best-characterized safety information available for this molecule — not because it certifies any compounded semaglutide preparation.

The bottom line

Compounded semaglutide occupies a real but narrowing space: no FDA approval, no FDA premarket review for safety, effectiveness or quality, a documented FDA record of dosing errors and at least one subpotent lot caught in writing, and a shortage pathway that has now closed. For some people compounded semaglutide is how GLP-1 care becomes affordable at all; for others the branded products are the better fit. What makes either path responsible is the same thing: a medical provider licensed in your state deciding what is appropriate for you, a licensed pharmacy dispensing it, and honest labeling of what it is and is not.

Talk it through with a provider, not a sales page. Our intake takes about 3 minutes and costs nothing. A medical provider licensed in your state reviews your health history — usually within 48 hours — and recommends what's actually appropriate, whether that's compounded, brand-name, or neither. You're never charged unless a provider approves your plan.

[See If You Qualify → https://start.itsladiesfirst.com/]

Keep reading

• Explore the weight program
• Compounded semaglutide, explained
• Is compounded semaglutide FDA-approved?

Sources

1. U.S. Food and Drug Administration — FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Updated June 15, 2026. (Salt forms; adverse-event counts as of May 31, 2026; underreporting; storage; fraudulent labels; warning signs.)
2. U.S. Food and Drug Administration — FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. July 26, 2024. (Five- to 20-fold dosing errors; varying concentrations; reported adverse events.)
3. U.S. Food and Drug Administration — FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Updated April 2026. (Semaglutide absent from the shortage list and the 503B bulks list; end of the 503A enforcement-discretion period; “essentially a copy” conditions.)
4. U.S. Food and Drug Administration — FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. April 30, 2026. (No clinical need identified; comment period through June 29, 2026.)
5. U.S. Food and Drug Administration — Warning Letter, Boothwyn Pharmacy, LLC (717525). January 16, 2026. (Semaglutide 2.5mg/mL Injection subpotent at 79.876%; adulterated under FD&C Act §501(c); misbranded under §502(a).)
6. Wegovy® (semaglutide) injection — FDA prescribing information via DailyMed. (Acute pancreatitis warning and patient instruction; describes the FDA-approved branded product only.)
7. 21 CFR Part 216 — Human Drug Compounding (eCFR, Title 21). (The federal compounding rules implementing FD&C Act §§503A and 503B.)